To Get Full Access :

Login with Linked
Login with Gmail

Follow us on

Link Linkedin Youtube

Ziihera

Ziihera is the first and only approved bispecific antibody drug. It treats unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. This drug is given to patients who have already received the other chemotherapeutic treatment.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

  • Molecule Name :

    Zanidatamab-Hrii

  • Innovator :

    JAZZ PHARMACEUTICALS

  • Approval Date :

    20-Nov-24

  • Data Exclusivity Expiry :

    20-Nov-28

  • Market Exclusivity Expiry :

    20-Nov-36

  • Dosage Form :

    Intravenous Infusion

  • Strength :

    30mg/vial

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    1

Year-wise Projected Sales ($M) :

  • 2025 :

    29

  • 2026 :

    92

  • 2027 :

    235

  • 2028 :

    376

  • 2029 :

    555

  • 2030 :

    790

  • 2031 :

    981
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login With

For full access Sign-up / Sign-in using below Methods:

Linked
Gmail

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?